Prostate Cancer - Results from #1100

Beyond the Abstract - Circulating tumor cells in prostate cancer: A potential surrogate marker of survival, by Jérôme Doyen and Catherine Alix-Panabières October 28, 2011

Beyond the Abstract - Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program, by Meelan Bul, MD, et al October 27, 2011

Beyond the Abstract - Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients, by Daniel Castellano, MD October 21, 2011

Beyond the Abstract - Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone, by James L. Mohler, MD, Mark A. Titus, PhD and Elizabeth M. Wilson, PhD October 14, 2011

Beyond the Abstract - Influence of antiflatulent dietary advice on intrafraction motion for prostate cancer radiotherapy, by Irene M. LIps, MD October 5, 2011

Beyond the Abstract - Physician beliefs and practices for adjuvant and salvage radiation therapy after prostatectomy, by Nitin Ohri, MD October 3, 2011

Beyond the Abstract - Correlation of hepatitis C and prostate cancer, inverse correlation of basal cell hyperplasia or prostatitis and epidemic syphilis of unknown duration, by Annika Krystyna, MD and Murray David Schwalb, MD September 21, 2011

Beyond the Abstract - Treatment options for localized prostate cancer, by Ravinder Mohan, MD, PhD September 16, 2011

Beyond the Abstract - High intensity focused ultrasound in clinical tumor ablation, by Yufeng Zhou, PhD September 13, 2011

Beyond the Abstract - Watchful waiting and active surveillance approach in patients with low risk localized prostatic cancer: An experience of out-patients clinic with 12-year follow-up, by Sergey Kravchick, MD September 9, 2011

Beyond the Abstract - Disease-specific survival of men with prostate cancer detected during the screening interval: Results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up, by Xiaoye Zhu, MD, et al September 7, 2011

Beyond the Abstract - Reverse stage shift at a tertiary care center: Escalating risk in men undergoing radical prostatectomy, by Vincent P. Laudone, MD and Jonathan Silberstein, MD September 6, 2011

Beyond the Abstract - Survival is associated with time to reach PSA nadir (DAN) and the ratio DAN/nadir value after androgen deprivation for prostate cancer, by Jacques Irani, MD August 25, 2011

Beyond the Abstract - Bone scan overuse in staging of prostate cancer: An analysis of a Veterans Affairs cohort, by Roland Palvolgyi August 17, 2011

Beyond the Abstract - Effect of testosterone administration to men with prostate cancer is unpredictable: A word of caution and suggestions for a registry, Alvaro Morales, MD, FRCS(C), FACS August 15, 2011

Beyond the Abstract - Increasing low risk prostate cancer incidence in United States Air Force servicemen and selection of treatments, by Jeri Kim, MD, Patricia Parker, PhD, and Douglas Boyd, PhD August 11, 2011

Beyond the Abstract - Focal therapy with high-intensity focused ultrasound for prostate cancer in the elderly. A feasibility study with 10 years follow-up, by Eric Barret, MD August 9, 2011

Beyond the Abstract - The health and well-being of prostate cancer patients versus male-to-female transsexuals on androgen deprivation therapy: A qualitative study with comments on expectations and estrogen, by Richard Wassersug, PhD July 19, 2011

Beyond the Abstract - Role of estrogen in normal male function: Clinical implications for patients with prostate cancer on androgen deprivation therapy, by Richard J. Wassersug, et al July 14, 2011

Beyond the Abstract - Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer, by Joey Cheung July 13, 2011

Page 56 of 58